Phone-based Intervention under Nurse Guidance after Stroke (PINGS): study protocol for a randomized controlled trial by Fred Stephen Sarfo et al.
STUDY PROTOCOL Open Access
Phone-based Intervention under Nurse
Guidance after Stroke (PINGS): study
protocol for a randomized controlled trial
Fred Stephen Sarfo1,2*, Frank Treiber3,4,5, Carolyn Jenkins4, Sachin Patel3,4, Mulugeta Gebregziabher6, Arti Singh1,
Osei Sarfo-Kantanka2, Raelle Saulson3, Lambert Appiah2, Eunice Oparebea2 and Bruce Ovbiagele7
Abstract
Background: Hypertension is the premier modifiable risk factor for recurrent stroke. In sub-Saharan Africa (SSA)
where the stroke burden is escalating, little is known about the role of behavioral interventions in enhancing blood
pressure (BP) control after stroke.
Our objective is to test whether an m-Health technology-enabled, nurse-led, multilevel integrated approach is
effective in improving BP control among Ghanaian stroke patients within 1 month of symptom onset compared
with standard of care.
Methods: This two-arm cluster randomized controlled feasibility pilot trial will involve 60 recent-stroke survivors.
Using a computer-generated sequence, patients will be randomly allocated into four clusters of 15 patients each
per physician: two clusters in the intervention arm and two in the control arm. Patients in the intervention arm will
receive a simple pillbox, a Blue-toothed UA-767Plus BT BP device and smartphone for monitoring and reporting
BP measurements and medication intake under nurse guidance for 3 months. Tailored motivational text messages
will be delivered based upon levels of adherence to the medication intake. Both groups will be followed up for
6 months to compare BP control at months 3, 6 and 9 as primary outcome measure. Physicians assessing BP
control will be blinded to arms into which patients are allocated. Secondary outcome measures will include
medication adherence scores and Competence and Autonomous Self-regulation Scale scores. A qualitative study
is planned after follow-up to explore the lived experiences of participants in the intervention arm.
Discussion: A feasible and preliminarily effective intervention would lead to a larger more definitive efficacy/
effectiveness randomized controlled trial powered to look at clinical events, with the potential to reduce
stroke-related morbidity and mortality in a low- to middle-income country.
Trial registration: ClinicalTrials.gov Identifier: NCT02568137, registered on 13 July 2015.
Abbreviations: BP, Blood pressure; BT, Blue-toothed; DBP, Diastolic blood pressure; GLMM, Generalized linear mixed
models; HTN, Hypertension; MPR, Medication Possession Ratio; PINGS, Phone-based Interventions under Nurse
Guidance after Stroke; RCT, Randomized controlled trial; SBP, Systolic blood pressure; SC, standard care;
SMASH, Smart phone Med Adherence Stops hypertension; SMS, Short Message Service; SSA, sub-Saharan Africa
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Background
Hypertension (HTN) is the premier modifiable risk fac-
tor for recurrent stroke [1]. Fortunately, with control of
HTN [2], recurrence of and mortality from stroke can
be greatly reduced [3–5] as has been seen in several
high-income countries (HICs) [6–9]. However, for low-
and middle- income countries (LMICs) that dispro-
portionately bear the global burden of stroke, these gains
have not materialized [10]. Data from the Global Burden
of Disease 2013 study suggest that deaths and disability-
adjusted life years from stroke in LMICs account for
75.2 % and 81.0 % of global estimates, respectively [11].
Achieving and sustaining blood pressure (BP) control
is a global challenge [12] particularly in LMICs including
sub-Saharan Africa (SSA) [12–14]. A multinational sur-
vey has identified that 46.5 % of participants with HTN
were aware of the diagnosis and 32.5 % of hypertensive
participants had their BP controlled, with rates of
awareness and control of BP significantly higher in HICs
compared with LMICs [12]. Key factors responsible for
uncontrolled HTN are medication non-adherence and
failure to intensify therapy in a timely manner (i.e.,
therapeutic inertia) [15, 16]. Furthermore, the lack of
availability, poor affordability and low rates of utilization
of secondary prevention cardiovascular medicines in
LMICs [17, 18] combined with low literacy levels, trad-
itional beliefs and misconceptions about HTN may all
contribute to the low prevalence of HTN awareness,
treatment and control which poses a serious threat to
stroke prevention.
Systematic reviews of randomized controlled trials
(RCTs) involving uncontrolled hypertensive patients have
indicated that BP self-monitoring, medication-reminding
tactics and the use of case managers each improve adher-
ence, therapeutic inertia and BP levels [19–22]. No RCTs
looking at medication adherence or BP self-monitoring
have been designed specifically for people in SSA, espe-
cially for those at high risk for future stroke. However, mo-
bile health (m-Health) technology offers a promising
approach to address this need [23–30]. Most adults in SSA
own a cell phone (approximately 73 %) [31, 32], smart-
phone ownership is burgeoning (approximately 35 %) [33],
and m-Health has produced promising results in chronic
disease management (e.g., HIV) in SSA [34–36].
An iterative, theory-guided, design process was used by
our group to develop an m-Health BP self-management
control program for poor, rurally located Hispanic
and African American hypertensive patients called the
Smartphone Med Adherence Stops Hypertension: SMASH)
[37, 38]. SMASH included multilevel components:
Patient-level interventions included: (1) sequential
automated reminder signals, (2) tailored Short
Message Service (SMS)/voice mail motivational and
reinforcement messages based upon adherence to
daily medication adherence and BP monitoring (every
3 days); and provider-level interventions entailing: (a)
emailed summary reports with stepped care guidelines at-
tached every 2 weeks, (b) phone alerts to clinic nurse navi-
gator when verified out-of-range BP measurements occur.
Several 3- and 6-month pilot RCTs were conducted with
Hispanics and African Americans with uncontrolled
HTN. In each RCT, we observed high acceptability,
self-efficacy for following a medical regimen, 95–100 %
medication adherence, a mean of 95 % achieving
guideline-designated BP control compared to an average
of 18 % in standard care (SC) patients and large systolic
blood pressure (SBP) reductions (mean: -32 mmHg)
[39, 40]. SMASH is capable of adaptation to other poor,
undereducated patients with HTN using an iterative
patient/provider-centered design approach.
The Phone-based Intervention under Nurse Guidance
after Stroke (PINGS) study is fashioned after the SMASH
program. The objective of the PINGS study is to test
whether a theoretical-model-based, m-Health technology-
enabled, multilevel integrated approach is feasible in im-
proving sustained BP control among 60 recent Ghanaian
stroke patients within 1 month of their stroke, while
building capacity in Ghana for longer-term testing of
m-Health technology for chronic disease management in
this resource-limited setting. A nurse navigator will be
employed in the study design as a task-shifting strategy in
the care of chronic diseases in SSA where there is a peren-
nial paucity of neurologists and physicians [41].
Methods
Trial design
This is a two-arm cluster randomized controlled trial in-
volving 60 stroke survivors with the physician as unit of
randomization and patients as unit of analysis. Each of the
four physicians will be recruited and randomly assigned to
the intervention or control group by the statistician (who
is not involved in provider or patient recruitment nor data
collection) using a computer-generated random sequence.
Four groups/clusters of 15 eligible patients will be assigned
to either control or intervention arms by the study coord-
inator after having met study criteria for enrollment (Fig. 1).
A cluster randomized trial has been chosen to avoid poten-
tial treatment contamination in which physicians might
unintentionally provide patients with different degrees of
attention or blending of treatment protocols. The checklist
for the study protocol is provided as Additional file 1.
Study setting
This study will be conducted at the Neurology Clinic in
Komfo Anokye Teaching Hospital, a tertiary referral
center in Kumasi, Ghana [42].
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Study participants
The participants will be 60 adult Ghanaian recent-stroke
patients (within 1 month of stroke onset) with uncon-
trolled HTN who meet the inclusion/exclusion criteria.
SBP ≥140 mmHg is used as the selection variable since
most patients with HTN who are aged below 65 years have
systolic or combination systolic/diastolic hypertension and,
for the majority, controlling SBP results in diastolic blood
pressure (DBP) also being controlled [43, 44].
Inclusion criteria
1. Above the age of 18 years; male or female
2. A stroke diagnosis no longer than 1 month before
enrollment
3. Have uncontrolled HTN (SBP ≥140 mmHg) based
upon last pre-stroke inpatient or outpatient encounter
clinic within the previous 12 months, as well as
post-stroke encounter and at the screening/
recruitment visit
4. Must be legally competent
5. Must own or have a close home-sharing family
member with a cell phone
Exclusion criteria
1. Failure to meet any of the inclusion criteria
2. Severe cognitive impairment/dementia (Modified
Mini-Mental State Examination (MMSE) score ≤24)*
3. Severe global disability (modified Rankin Scale
(mRS) score ≥3)*
4. Renal dialysis; awaiting renal transplant or transplant
recipient
5. Cancer diagnosis or treatment in the past 2 years
6. Planned pregnancy
7. Vulnerable populations, such as pregnant or nursing
women, prisoners and institutionalized individuals
*MMSE score ≤24 and global disability (mRS)
score ≥3 excludes patients who have severe cognitive
impairments and medical limitations that would




Patients in the intervention group will be given an inexpen-
sive simple pillbox and loaned a Blue-toothed UA-767Plus
BT BP device along with a medical regimen assistance ap-
plication for their smartphone for automatic relay of BP
data to a central server at the Medical University of South
Carolina. Patients needing a loaner 2 or 3G phone will
receive one. The PINGS nurse navigator and patient will
establish times that antihypertensive medications and
other medications such as antiplatelet agents, statins and
oral hypoglycemic agents will be taken daily for entry
into the application. The patient (and caregiver) will
show that they can properly load the pill tray, view the BP
protocol demonstration video and successfully take three
Fig. 1 Phone-based Intervention under Nurse Guidance after Stroke (PINGS) study algorithm
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consecutive BP measurements using the app’s protocol,
and view the feedback chart and/or see their immediate
BP data from that session on their phone.
They will receive written and oral information on
adherence criteria:
1. To take their medications within 2 hours of
designated times,
2. To take their BP every 3 days in the morning and
evening
A list of motivational and reinforcement messages will
be developed by adapting ones used in earlier m-Health
BP control studies [38–40] and enhancing them guided by
self-determination theory constructs of competence and
autonomous self-regulation [45, 46]. These tailored brief
SMS messages will be based on the previous day’s re-
ported medication adherence levels. After two consecutive
weeks of 100 % adherence (i.e., medication intake reports
using established algorithms based upon proximity to pre-
established times for pill intake, using time stamps of
when doses were taken, sent via phone) and verification
with Medication Possession Ratios (MPRs), the schedule
of SMS message delivery will switch to a variable interval
schedule [38, 47]. Messages will be tapered to several
times per week on a 3-day average variable interval
schedule unless adherence drops to below 90 %.
Patients will receive a SMS reminder message on the
morning that they are to take their BP measurements.
They will receive a tailored SMS message reinforcing
their having taken their BP measurements the day after
doing so. After each BP session, patients will receive
visual BP feedback on their phone, and can select charts
showing cumulative averages across weeks/months com-
pared to BP control threshold lines. Patients will also re-
ceive lifestyle tips via SMS.
After completion of the 3-month trial, patients will
return the BP monitors (and smartphones). Those who
experience delayed monthly refill (more than 3 days from
the designated time) or uncontrolled BP or a missed ap-
pointment on two occasions at the standard 3-month
clinic visit will be called by the nurse navigator. The nurse
navigator will be trained to conduct motivational inter-
viewing to help these patients identify barriers/issues and
develop an action plan. This may include a patient re-
starting some PINGS’ components (e.g., medication intake
reminder alert via SMS delivery system reactivation,
motivational messages), being referred for additional help
(e.g., mental health), and so forth.
Provider level
Physicians in the intervention arm will receive summary
reports of their patients’ adherence to their medications
and BP data tailored by them (e.g., average and range of
SBP/DBP readings, percent of SBP/DBP controlled, and
so forth) every 2 weeks using only patient ID numbers.
They will also receive summary charts of expert consen-
sus BP management guidelines used in other studies
[47]. If a patient’s mean BP exceeds the thresholds, the
PINGS nurse navigator will call the patient and conduct
the BP protocol again, and initiate a follow-up action as
needed. The nurse navigator will also contact those pa-
tients who show medication adherence below .80 and/or
whose monthly MPRs do not reflect the information in
the self-reported medication intake summary reports.
They will use motivational interviewing to help the pa-
tient to eliminate the barriers related to poor medical
regimen adherence.
Control arm/standard of care
Inclusion criteria include owning a cell phone with at least
SMS and voice mail. To control for attention exposure,
they will receive SMS messages dealing with healthy life-
style behaviors (smoking, diet, physical activity) but not
with medication adherence, hypertension- or stroke-
related issues. Messages will be of the same frequency and
size as those in the intervention arm. Every 3 days (com-
parable to those in the intervention arm) they will receive
lifestyle messages and if they have a smartphone, the SMS
messages will have either PDFs attached or weblinks to a
brief video clip or series of charts, information, and so
forth. This information will be sent in two messages and
requires 3–5 min per message to view or listen to (similar
to the BP protocol duration). All four physicians will re-
ceive the expert consensus guideline charts. Intervention
tactics will cease for both groups after the 3-month trial.
Follow-up phase
Subjects in both arms of the study will be followed up for
6 months after the initial 3-month trial. During the follow-
up period, subjects will attend clinics monthly where their
physicians will assess them clinically. At months 3, 6 and 9
post enrollment patients and providers will undergo
assessments on methodological parameters and consumer
responses, clinic BP measurements, medication adherence,
health literacy on stroke and HTN as well as self-
determination theory constructs such as Autonomous Self-
regulation and Competence Scales. Physicians in both
groups will also undergo assessment on adherence to BP
management protocols (Fig. 1 and Table 1).
Outcome measures
Feasibility outcomes
This will include recruitment and dropout proportions,
protocol adherence, as well as patient and provider satis-
faction at 3, 6 and 9 months.
Sarfo et al. Trials  (2016) 17:436 Page 4 of 10
Primary outcome measures
This will include percent success in reaching BP control
(Table 2) and changes in clinic BP measurements.
Secondary outcome measures
These will include outcomes such as MPR, Morisky
Medication Adherence Scale (MMAS) score and Com-
petence and Autonomous Self-regulation Scale scores.
Table 1 shows all outcome variables, questionnaires to
be used and when they will be administered. We will as-
sess self determination theory-related constructs of com-
petence [48, 49], and autonomous self-regulation [50, 51].
We will also assess HTN knowledge [52, 53], medication
side effects, stroke knowledge, self-reported medication
adherence (MMAS), beliefs and life goals [54, 55] and
MPR [56].
Participant timeline
Algorithms for participant recruitment and follow-up as-
sessments are shown in Fig. 1.
Proposed sample size
For this feasibility cluster RCT we will recruit 15 patients
per cluster (i.e., physician), 30 patients per group (inter-
vention versus control group) (total n = 60). We agree
with Kraemer et al. [57] that pilot feasibility studies are de-
ficient in estimating effect size with sufficient accuracy for
future study design. To this end we will evaluate the
availability of subjects, assess proportions approached/
consented, and examine the feasibility of PINGS by evalu-
ating adherence and retention rates. Thus, sample size
justification focuses on the precision of estimates rather
than the power of statistical tests. We will recruit 30 sub-
jects (15 per physician = cluster) per treatment group
based on number of degrees of freedom within each
cluster, as suggested by Mead, to obtain reasonable preci-
sion for variance estimates [58].
Recruitment
A list of eligible patients will be identified from hospital
medical records by a research assistant (RA) with the
identity of the patients’ doctors not included. The
Table 1 Study outcome measures




Feasibility: methodological parameters and
consumer responses
Recruitment and retention rates;
Self-report: Patient/Provider Satisfaction Scale (.82–.96,
test-retest (1 week) .98) [74, 75], fidelity checklists: patient level
(e.g., connection; BP uploads via phone; opening of messages/
educational information and provider level (e.g., delivery of
provider summaries; phone alerts)
Baseline, 3, 6, 9 months
Clinic: BP Clinic-based BP
Feedback and refinement Focus groups Providers and IG: 9 months
Secondary outcomes
Medication adherence Physician adherence Medication Possession Ratio (MPR); Morisky Medication
Adherence Scale (α = .76–.83, r = .64) [76, 77], provider
guideline adherence: timely med changes (date of script
changes following BP feedback (bi-monthly PINGS reports/
clinic BPs)
Baseline, 3, 6, 9 months
Self-determination theory constructs Autonomous Self-Regulation (α= .81–.84, r = .38) [78], Competence
Scale (α= .88–.95, r = .32–.46) [51, 52, 78].
Potential moderators/mediators
Demographics Age, education level, income Baseline
HTN/stroke knowledge, health literacy,
anthropometrics
Self-report: HTN/stroke knowledge (.70) [54, 55], health literacy
(r = .74, .82) [78–80],
Height/ weight/girth
Baseline, 3, 6, 9 months
Medication adherence factors Side effects, adverse events As reported, and 3, 6, 9 months
aBasic psychometric property analyses (e.g., internal consistency, test-retest reliability) will be conducted during first 3 months on scales, which have not been
used with Ghanaian stroke patients
BP blood pressure, HTN hypertension, IG Intervention Group




Clinic blood pressure control will be defined at
resting systolic blood pressure of <140 mmHg
and or diastolic blood pressure of <90 mmHg
Medication
adherence
Medication adherence will be categorized using
Medication Possession Ratios into: Excellent 100 %
Good 80–99 % and Poor <80 %.
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research coordinator (RC) will contact and schedule eligible
patients for screening/recruitment and obtain informed
consent voluntarily from patients who are interested in the
study. Subjects whose SBP averages ≥140 mmHg from the
last two readings of the 10-min protocol will have their
height, weight and waist circumference measured. A set of
questionnaires will be administered to assess study
outcome measures (see Table 1). The study site admits
an average of 43 stroke patients each month. Based upon
the stroke with HTN incidence patterns in the KATH and
SMASH pilot work [38–40, 47], we will recruit eight pa-
tients (four intervention group patients and four control
group patients) per month for enrollment into the study.
Allocation and concealment
Randomization of subjects in blocks of four will be con-
ducted by a statistician using a computer-generated ran-
dom sequence of numbers. Participants who consent to
the study will be allocated to either of the two interven-
tion clusters or the two control clusters at the baseline
visit using the computer-generated randomization se-
quence. Each sequence generated will be kept concealed
in an envelope which will be opened by the research co-
ordinator in the presence of the consenting eligible study
participant at enrollment.
Blinding
Physicians who will be assessing primary outcomes and
research assistants assessing feasibility and secondary
outcomes will remain blinded as to the patients’ group
status throughout study (i.e., preintervention, 3-, 6- and
9-month evaluations).
Data collection and management
Instruments and questionnaires for data collection are
listed in Table 1. Data will be entered into REDCap and,
to promote excellent data quality, double data entry by
two independent data entry clerks will be performed.
Planned refinement of the PINGS program
We will refine the PINGS content, delivery format and
feedback mechanisms for initial and sustained use, based
on subjects’ adherence data, responses to adherence feed-
back, providers’ responses and other variables that might
influence optimal use of the PINGS study [59, 60]. We
propose that, over time, positive feedback (including
immediate BP feedback, medication adherence feedback,
motivational/reinforcement messages) will create sustained
behavior change. Although insufficiently powered for for-
mal mediation analyses, we will explore relationships via
structural equation modeling using self-determination the-
ory constructs of subjects’ competence (Competence Scale
scores) and autonomous regulation (Autonomous Self-
Regulation Scale scores) with changes in primary clinical
outcomes (changes in BP control, BP and medication ad-
herence), which will help guide further PINGS’ refinement.
Providers’ and patients’ attitudes and treatment satisfaction
play important roles in the degree to which an intervention
is adopted [61–63]. This information will guide how
PINGS is presented to the Ghanaian health care commu-
nity assuming that the feasibility trial and future efficacy/
effectiveness RCTs are successful.
Statistical analyses
Feasibility outcomes
We will use 95 % confidence intervals (CIs) for propor-
tions to estimate dichotomous outcomes (e.g., propor-
tion agreeing to participate); adherence to protocol (e.g.,
use of a medication pill tray, use of a smartphone to
send BP measurements, opening of SMS/voice mail
messages, and so forth). Frequency distributions will be
developed describing reasons for provider and patient
protocol nonadherence, dropout and problems encoun-
tered such as technology glitches, medication side effects,
and so forth. For continuous measures (e.g., patient satis-
faction scores), frequency distributions and median and
mean responses (with 95 % CIs) will be used. Chi-square
tests (categorical measures) and pooled t tests (or
Wilcoxon rank sum tests) for continuous measures will
compare intervention group and SC groups.
Primary outcome measures
For these measures, generalized linear mixed models
(GLMM) will be used to compare the two groups with
group as primary independent variable and percent
success reaching BP control (or resting BP changes indi-
vidually) as the primary dependent variable (Table 2) [64].
GLMM allow for missing data, measurement at different
times and take into account the effect of clustering, i.e.,
correlation of repeated measurements within patients
clustered within MD (Medical Doctor) provider. Group
and time (baseline, 3, 6 and 9 months) will be fixed effects;
demographics and secondary outcome measures (e.g.,
medication adherence via the MPR) will be adjustment
covariates. We will assess changes over time via a time-
by-intervention interaction term in multivariable models.
We will estimate differences (for means or proportions) in
ancillary moderator and mediator measures between the
two groups via 95 % CIs as appropriate (e.g., self-efficacy,
autonomous regulation, and so forth.). We will estimate
differences (via 95 % CI) in proportions and average slopes
between intervention versus control groups and evaluate
linearity of trajectories as input for future RCT analysis
strategy. We will estimate percent success reaching BP
control for each subject over the trial (baseline, 3, 6 and
9 months), and the within-subject longitudinal trajectories
(e.g., slopes), and then summarize as mean longitudinal
trajectory within each treatment group (e.g., mean slopes
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with 95 % CI). Intracluster correlation coefficient (ICC) and
variance estimates will be obtained of efficacy outcomes
and covariance structure of the longitudinal scores for de-
termination of sample size (and hence adequate power) for
a future RCT. Multiple imputation methods will be used
for missing end-of-study outcomes. Dropout rate, both se-
lective and differential, is an important issue. If more than
10 % of data are missing, we will add an intermediate evalu-
ation point in a future RCT to provide more data for use in
endpoint imputation.
Secondary outcome measures
These are categorical (percent of patients and providers
who were adherent) and continuous (e.g., MPR, MMAS
score; Competence and Autonomous Self-regulation
Scale scores). GLMM will compare the two groups with
treatment group as primary independent variable, and
outcome measures individually as the dependent vari-
ables [64]. Group and time (baseline, 3-, 6- and 9-month
visit) will be included as fixed and physician as random
effects; health literacy, demographics (age, gender, and
so forth) and HTN/stroke knowledge will be adjustment
variables. Ninety-five percent CIs will be reported.
Qualitative studies
After final follow-up (month 9), approximately 10 patients
in the intervention group will be randomly selected (5 per
physician cluster) to be in a focus group (FG – two will be
conducted) of “lived experiences”. Topic areas with probes
will cover expectations, experiences, adherence, motiv-
ation and advice from family [3, 31, 32]. The two PINGS’
physicians, nurse navigator and other staff involved in
the PINGS delivery will also be invited to be in a FG
(n = approximately 5–8). We will assess attitudes, beliefs,
barriers and facilitators for use, as well as feedback on re-
tention, fidelity, impact upon therapeutic inertia and other
practice considerations. FGs will be audio-recorded, notes
taken, transcribed and imported into NVivo 10.0 for ana-
lyses [65]. We will use the constant comparative method
of qualitative analysis to code the data [66, 67]. Tran-
scripts will be independently reviewed and coded by two
reviewers. Once no new themes emerge, thematic satur-
ation will have been reached [68]. We will then compare
and contrast themes from participants and providers using
the triangulation approach [69].
Data Monitoring Committee (DMC)
Our feasibility RCT will not have a DMC due to its pre-
liminary and exploratory nature.
Discussion
To our knowledge, this would be the first study in SSA
to apply synergistic constructs from behavioral and tech-
nology application theories and direct guidance from
stroke patients, providers and administrators. Secondly,
we propose to use real-time adherence measurements of
BP data and medication intake to facilitate immediate
feedback, and automated motivational/reinforcement
messages, all aimed at enhancing self-determination
theory constructs of competence (akin to self-efficacy)
and autonomous regulation (sustained internally driven
motivation). Thirdly, our protocol will give health care
providers personally designed automated reports to en-
able faster changes in medication regimens and earlier
sustained BP control.
A feasible and preliminarily effective PINGS’ interven-
tion would lead to a larger, more definitively efficacious
RCT powered to look at clinical events, with the poten-
tial to reduce HTN-related stroke morbidity, mortality
and associated costs in SSA. Second, the proposed task-
shifting strategy, which uses nurses to direct BP control,
could potentially mitigate the critical shortage of health
care workers in the region, and leveraging the high (and
rising) mobile phone penetration in the region could
integrate care systems and improve patient-provider
communication. Third, through our iterative behavioral
change theory-guided design process we will be asses-
sing post-trial acceptability, satisfaction, usability, sali-
ence and aids/barriers to sustainability among patients,
caregivers, providers and other key stakeholders. This in-
formation will provide information as to how the PINGS
patient- and provider-developed m-Health program in
SSA can be refined and eventually disseminated to other
locales (assuming that follow-up trials are also effective).
Finally, early stage SSA investigators are involved in the
PINGS study, which is key for building future research
capacity in SSA. Several PINGS team members have suc-
cessfully mentored junior faculty who have become inde-
pendently funded investigators and will serve as mentors
for the coinvestigators and their research administration
staff in Ghana. This will include a progressive exposure
to key publications, pod-cast lectures; and direct engage-
ment in trial design, human subject management and
execution of a theory-guided m-Health program for ad-
dressing chronic disease management. Our collaborators
will also receive educational information on the process
of developing m-Health research capacity within their
hospital network.
Possible limitations to the PINGS study may include
the lack of a longer feasibility trial and a lack of intensive
lifestyle programs. In response to the first limitation, our
selection of a 3-month trial and 6-month follow-up was
guided by BP control trials which usually ran for 1–6
months and had no follow-up [20, 21]. A future efficacy
RCT will assess if BP control is sustained beyond
9 months. Our approach to the lack of intensive lifestyle
programs will be to first focus on how medication adher-
ence and BP monitoring impact BP control without
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including additional tactics. This is based upon financial
costs, response burden and primary practice-based HTN
RCTs which found that: (1) adding lifestyle programs to
BP monitoring or medication reminder tactics, and so
forth, does not necessarily enhance BP control [70] and
(2) lifestyle programs are difficult to implement and sus-
tain [71–73]. Also, providers repeatedly request easy-to-
implement and efficacious programs. We will have a
wealth of data to address important issues not detailed
which will guide our future work (e.g., triangulation of
the MMAS self-report, pharmacy records (MPR) data to
develop effective algorithms for medication adherence
measurement). Additional moderator/mediator (under-
standing they are perhaps underpowered) analyses will
be conducted examining the influence of acculturation,
health literacy, HTN/stroke knowledge and so forth
upon medication adherence and BP control.
Trial status
Recruitment is anticipated to begin in April 2016.
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